Last edition
News about "zenocutuzumab-zbco"
Partner Therapeutics Wins FDA Approval for BIZENGRI in NRG1+ Cholangiocarcinoma
Partner Therapeutics receives US Food and Drug Administration (FDA) approval for BIZENGRI, the first targeted therapy for NRG1 fusion-positive cholangiocarcinoma, expanding use across NSCLC and pancreatic cancer.
Zenocutuzumab-zbco | 12/05/2026 | By News Bureau
FDA Grants Orphan Drug Designation to Zenocutuzumab for Rare Cholangiocarcinoma Subset
Partner Therapeutics secures Orphan Drug Designation for zenocutuzumab-zbco in NRG1 fusion-positive cholangiocarcinoma, strengthening development of targeted therapy for this aggressive rare cancer.
Zenocutuzumab-zbco | 09/02/2026 | By News Bureau | 136
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy